Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.

Cancer
S O'BrienH Kantarjian

Abstract

Understanding the causes of failure in older patients with acute lymphocytic leukemia (ALL) may help improve treatment strategies for patients in this particular age group. The objectives of the current study were to define the causes of death in older patients (aged > or = 60 years) with ALL during induction and consolidation-maintenance with a dose-intensive regimen of alternating 8 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) with high doses of methotrexate and cytarabine followed by maintenance with 6-mercaptopurine, vincristine, methotrexate, and prednisone and to compare their outcomes with the outcomes of older patients who received earlier, less intensive regimens and younger patients who received hyper-CVAD. One hundred twenty-two older patients who received hyper-CVAD were compared with 34 older patients who received less intensive regimens and with 409 younger patients who received hyper-CVAD. The complete response (CR) rates in older patients receiving hyper-CVAD, older patients receiving other regimens, and younger patients receiving hyper-CVAD were 84%, 59%, and 92%, respectively (P < .001); and the respective induction mortality rates were 10%, 12%, and 2...Continue Reading

References

Jun 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M KantarjianB Barlogie
Aug 27, 1998·The New England Journal of Medicine·C H Pui, W E Evans
Jan 9, 2001·Hematology/oncology Clinics of North America·N GökbugetD Messerer
Jan 9, 2001·Hematology/oncology Clinics of North America·I J DurrantA H Goldstone
Jan 9, 2001·Hematology/oncology Clinics of North America·R A Larson
Jan 9, 2001·Hematology/oncology Clinics of North America·G Garcia-Manero, H M Kantarjian
Feb 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Forida Y MortuzaLetizia Foroni
Sep 26, 2003·Cancer·Stefan FaderlHagop M Kantarjian
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J KurtzbergB S Mitchell
Oct 1, 2005·Blood·Monika BrüggemannUNKNOWN German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Apr 18, 2006·Seminars in Hematology·Richard A Larson

❮ Previous
Next ❯

Citations

Apr 29, 2010·Current Hematologic Malignancy Reports·Amber FullmerElias Jabbour
Mar 30, 2013·Current Hematologic Malignancy Reports·Naval Daver, Susan O'Brien
Sep 15, 2011·Drugs & Aging·Philippe Rousselot, André Delannoy
Aug 28, 2013·Digestive Diseases and Sciences·Changying ChenLi Hao
Jan 9, 2010·Expert Opinion on Emerging Drugs·Amber FullmerElias Jabbour
Mar 5, 2016·Current Hematologic Malignancy Reports·Victor D FedorovAmir T Fathi
Jun 23, 2015·American Journal of Hematology·Mathilde Hunault-BergerUNKNOWN Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)
Sep 17, 2013·British Journal of Haematology·Marc Poch MartellJoseph M Brandwein
Oct 18, 2016·International Journal of Cancer. Journal International Du Cancer·Ishwaria M SubbiahApostolia M Tsimberidou
Nov 7, 2016·Mayo Clinic Proceedings·Shilpa PaulElias J Jabbour
Apr 19, 2017·European Journal of Haematology·Piotr KozlowskiUNKNOWN Swedish Adult Acute Lymphoblastic Leukemia Group (SVALL)
Jul 27, 2017·Leukemia & Lymphoma·Ibrahim Aldoss, Anthony S Stein
Feb 10, 2018·Current Hematologic Malignancy Reports·Nicholas J ShortFarhad Ravandi
Oct 3, 2018·Leukemia & Lymphoma·Kevin C MillerHassan B Alkhateeb
Feb 15, 2019·Journal of Oncology Practice·Ibrahim AldossVinod Pullarkat
Jan 27, 2010·Cancer·Stefan FaderlHagop M Kantarjian
May 17, 2019·Leukemia & Lymphoma·Hind RafeiElias J Jabbour
Oct 1, 2019·British Journal of Haematology·Hind RafeiElias J Jabbour
Dec 20, 2017·Drugs & Aging·Nicola Gökbuget
May 19, 2020·American Society of Clinical Oncology Educational Book·Daniel J DeAngeloAnjali Advani
Feb 17, 2017·Current Oncology Reports·Nicholas J Short, Elias Jabbour
Mar 28, 2020·Therapeutic Advances in Hematology·Iman Abou DalleNicholas J Short
Jan 4, 2018·Blood Advances·Elias Jabbour, Hagop Kantarjian
Oct 12, 2018·International Journal of Hematologic Oncology·Yazeed Sawalha, Anjali S Advani
Jun 7, 2020·Journal of Hematology & Oncology·Bachar SamraNicholas J Short

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.